Silverback Therapeutics

Our CEO, Laura Shawver (@lshawverO), will be presenting at the H.C. Wainwright (@HCWCO) 24th Annual Global Investment Conference. Tune in tomorrow, May 24th at 7:00 a.m. ET / 4:00 a.m. PT to hear the live webcast. bit.ly/3MFRdQ5 $SBTX

Our Silverback team was treated to #espresso drinks from Gourmet Espresso Catering (@mobilespresso). Thank you, Gourmet Espresso Catering, for bringing our team together! #OurStrengthIsOurPeople

Our Silverback management team will be participating in the H.C. Wainwright (@HCWCO) 24th Global Investment Conference from May 23-25, 2022. Learn more here: bit.ly/3Nobn0D $SBTX

Today, we announced our Q1 2022 financial results and provided a business update. Visit the ‘News & Events’ section of our website to learn more: bit.ly/3FDMBai $SBTX

May is #HepatitisAwarenessMonth – a time to recognize the global impact of hepatitis B and the need for increased testing, diagnosis & treatment. At Silverback, we are #SeekingVictory for the ~300M patients globally with chronic #HepB through our #SBT8230 program.

Activation of #TLR8 can elicit a robust immune response, critical for mounting productive anti-tumor and anti-viral responses, through a multi-pronged mechanism of action.

Today, our CEO, Laura Shawver (@lshawverO), will be presenting a corporate overview at the 42nd Annual @Cowen_Inc Healthcare Conference. Tune in at 9:50 a.m. PT / 12:50 p.m. ET to hear the live webcast. bit.ly/3uX3Zkh $SBTX

In honor of #InternationalWomensDay & #WomensHistoryMonth, we are recognizing the importance of having a diverse workforce with strong female leaders & employees. Hear from Silverback members on what #IWD & #WHM means to them.

At Silverback, we see immunotherapy as an important tool in the future of cancer treatment. We are focused on developing innovative, tissue-targeted immunotherapies that activate myeloid cells & stimulate an immune response against cancer. bit.ly/3ruqOMN #CancerMoonshot

The Cancer Moonshot initiative is a noble cause with the goal of cutting cancer death in half over the next 25 years.

Our CEO, Laura Shawver (@lshawverO), and President & CSO, Valerie Odegard, will be participating in a fireside chat at the @SVBLeerink 11th Annual Global Healthcare Conference today at 10:00 a.m. PT / 1:00 p.m. ET. View the webcast here: bit.ly/3gqHluY

Today, our CEO, Laura Shawver (@lshawverO), will be participating in an @endpts webinar entitled, “The top 100 VCs in biotech 2022” moderated by @JohnCendpts at 11:00 a.m. PT / 2:00 p.m. ET. Learn more and register here: bit.ly/3J3tWFl

We have an exciting year ahead of us at Silverback, with two clinical-stage oncology programs and a chronic HBV program in late-stage preclinical clinical development. #HER2 #Nectin4 #TLR8 #HBV

#HER2 #Nectin4

Today is #WorldCancerDay – With the theme #CloseTheCareGap, we recognize that everyone deserves access to cancer care. At Silverback, we are proud to have two clinical-stage programs in oncology with a TLR8 agonist payload targeting myeloid cells in the tumor microenvironment.

Grateful for the pioneers of immunotherapy whose enduring discoveries have brought hope to cancer patients everywhere. #WorldCancerDay

Join a team of individuals who love working together, set the bar high and are dedicated to developing new therapies for patients with cancer and other serious diseases. View open positions here: bit.ly/3K3iCKJ

On Martin Luther King Jr. Day – our team honors the life and legacy of Dr. King who focused his efforts on encouraging people to fight racial inequality and build stronger communities. #MLKDay

At Silverback, our mission is to seek victory for patients by developing novel, tissue-targeted therapies designed to result in life changing outcomes. As we enter 2022, we remind ourselves & our patient community of the values that guide us in our work. bit.ly/3pkP9DA

Our CEO, Laura Shawver (@lshawverO), and CSO and President, Valerie Odegard, provided a corporate overview at the @HCWCO Bioconnect 2022 Conference today. See the full webcast here: bit.ly/3uX3Zkh $SBTX